371 Results for: created: (01/2018 to 01/2018)

People

  1. Adusumilli
    Adusumilli
  2. Eguchi
    Eguchi
  3. Jones
    Jones
  4. Travis
    Travis
  5. Lu
    Lu
  6. Wu
    Wu
  7. Damato
    Damato
  8. Motzer
    Motzer
  9. Rimner
    Rimner
  10. Taggar
    Taggar

Groups

  1. Department of Medicine (148)
  2. Solid Tumor Oncology Division (96)
  3. Sloan Kettering Institute Postdocs (87)
  4. Surgery (81)
  5. GSK Faculty (76)
  6. Center for Hematologic Malignancies (50)
  7. Epidemiology and Biostatistics (48)
  8. Survivorship Research (48)
  9. Hematologic Malignancies, Division of (47)
  10. Department of Pathology and Laboratory Medicine (43)
  1. "2017"
Formats
  1. Journal Article (239)
  2. Meeting Abstract (118)
  3. Book Section (13)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (148)
  2. Solid Tumor Oncology Division (96)
  3. Sloan Kettering Institute Postdocs (87)
  4. Surgery (81)
  5. GSK Faculty (76)
  6. Center for Hematologic Malignancies (50)

More Groups

People
  1. Prasad Adusumilli (27)
  2. David Jones (19)
  3. Takashi Eguchi (19)
  4. William Travis (15)
  5. Abraham Wu (11)
  6. Shaohua Lu (11)

More People

Years
  1. 2017 (371)
Publications
  1. Journal of Thoracic Oncology (53)
  2. Neuro-Oncology (27)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (11)
  5. Brachytherapy (10)
  6. Leukemia Research (8)

More Publications

Publishers
  1. Elsevier Inc. (79)
  2. Oxford University Press (34)
  3. Elsevier Science, Inc. (29)
  4. Springer (19)
  5. American Association for Cancer Research (18)
  6. Wiley Blackwell (13)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)-refractory recurrent glioblastoma (GBM)
    Meeting Abstract

    Reardon, D.; Kaley, T.; Dietrich, J.; Clarke, J. L.; Dunn, G. P.; Lim, M.; Cloughesy, T.; Gan, H. K.; Park, A.; Schwarzenberger, P.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Lanreotide in patients with lung neuroendocrine tumors: The randomized double-blind placebo-controlled international phase 3 SPINET study
    Meeting Abstract

    Reidy-Lagunes, D.; Kulke, M.; Wolin, E.; Singh, S.; Ferone, D.; Hoersch, D.; Mirakhur, B.; Hoffmanns, P.; Houchard, A.; Caplin, M.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Comparability of the relative survival metrics among lung cancer patients and general population
    Meeting Abstract

    Tan, K. S.; Eguchi, T.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Appropriate endpoint for stage I NSCLC: Correlations of long-term survival with disease-free and recurrence-free survival
    Meeting Abstract

    Tan, K. S.; Eguchi, T.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • An analysis of the transcriptional response of myelodysplastic syndrome stem cells to therapy at single-cell resolution
    Meeting Abstract

    Chung, S.; Vijay, P.; Klimek, V.; Mason, C.; Park, C.
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a selective oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Identification of aberrant splicing events in myelodysplastic syndrome patients with splicing factor gene mutations
    Meeting Abstract

    Pellagatti, A.; Steeples, V.; Sharma, E.; Repapi, E.; Yip, B. H.; Armstrong, R. N.; Dolatshad, H.; Lockstone, H.; Taylor, S.; Giagounidis, A.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Characterization of novel oral splicing modulator, H3B-8800, identifies the mechanistic basis for its preferential lethality towards spliceosome-mutant myeloid malignancy models
    Meeting Abstract

    Buonamici, S.; Yoshimi, A.; Thomas, M.; Seiler, M.; Chan, B.; Csibi, A.; Fekkes, P.; Klimek, V.; Kumar, P.; Lee, S. C. W.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Preoperative needle biopsy and tumor spread through alveolar spaces (STAS) in resected lung adenocarcinomas
    Meeting Abstract

    Kameda, K.; Eguchi, T.; Lu, S.; Solomon, S.; Bott, M.; Jones, D.; Rekhtman, N.; Travis, W.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Immunotherapy for KRAS positive lung adenocarcinoma: Mesothelin and CA125 (MUC16) are cancer-antigen targets
    Meeting Abstract

    Hristov, B.; Eguchi, T.; Chintala, N.; Lu, S.; Bott, M.; Travis, W.; Jones, D.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save